33665-90-6Relevant articles and documents
Structural and IR-spectroscopic characterization of pyridinium acesulfamate, a monoclinic twin
Baran, Enrique J.,Piro, Oscar E.,Echeverría, Gustavo A.,Parajón-Costa, Beatriz S.
, p. 753 - 758 (2018)
The crystal structure of pyridinium 6-methyl-1,2,3,-oxathiazine-4(3H)-one-2,2-dioxide [(C5NH6)(C4H4NO4S)], for short, pyH(ace), was determined by X-ray diffraction methods. It crystallizes as a twin in the monoclinic space group P21/c with a=6.9878(9), b=7.2211(7), c=21.740(2) ?, β=91.67(1)° and Z=4 molecules per unit cell. The structure was determined employing 1599 reflections with I>2 σ(I) from one of the twin domains and refined employing 2092 reflections from both crystal domains to an agreement R1 factor of 0.0466. Besides electrostatic attractions, intermolecular pyH···O=C(ace) hydrogen bonds stabilize the acesulfamate anion and the pyridinium cation into planar discrete units parallel to the (100) crystal plane. The units form stacks of alternating ace- and pyH+ ions along the a axis that favors inter-ring π-π interactions. The Fourier transform-infrared (FT-IR) spectrum of the compound was recorded and is briefly discussed. Some comparisons with related pyridinium saccharinate salts are also made.
A new acesulfamato complex: [Cu(acesulfamato)2(H2O)4]. Structural and spectroscopic characterization
Baran, Enrique J.,Echeverría, Gustavo A.,Parajón-Costa, Beatriz S.,Piro, Oscar E.
, (2020)
The crystal structure of tetraaqua-bis(6-methyl-1,2,3-oxathiazin-4(3H)-onato 2,2-dioxide) copper(II) complex, for short [Cu(ace)2(H2O)4], was determined by X-ray diffraction methods. The complex crystallizes in the monoclinic C2/c space group with a = 11.9838(4), b = 9.5240(3), c = 15.1686(6) ?, β = 102.975(4)° and Z = 4 molecules per unit cell. The structure was determined from 1609 reflections with I > 2σ(I) and refined to an agreement R1-factor of 0.0345. [Cu(ace)2(H2O)4] is a new member in the family of acesulfamate complexes of first row transition metals, namely [M(ace)2(H2O)4], M: Co, Ni, Zn. It differs from the other members in the bonding of acesulfamate to metal through one of its sulfoxide oxygen atoms. The new complex was further characterized by its infrared, Raman and electronic absorption spectra, which were discussed in comparison with those of other related species.
Structural and IR-spectroscopic characterization of cadmium and lead(II) acesulfamates
Echeverría, Gustavo A.,Piro, Oscar E.,Parajón-Costa, Beatriz S.,Baran, Enrique J.
, p. 739 - 745 (2017)
Cadmium and lead(II) acesulfamate, Cd(C4H4NO4S)2 2H2O and Pb(C4H4NO4S)2, were prepared by the reaction of acesulfamic acid and the respective metal carbonates in aqueous solution, and characterized by elemental analysis. Their crystal structures were determined by single crystal X-ray diffraction methods. The Cd(II) compound crystallizes in the monoclinic space group P21/c with Z = 4 and the corresponding Pb(II) salt in the triclinic space group P1 with Z = 2. In both salts, acesulfamate acts both as a bi-dentate ligand through its nitrogen and carbonyl oxygen atoms and also as a mono-dentate ligand through this same oxygen atom, giving rise to polymeric structures; in the Pb(II) salt the ligand also binds the cation through its sulfoxido oxygen atoms. The FTIR spectra of the compounds were recorded and are briefly discussed. Some comparisons with other related acesulfamate and saccharinate complexes are made.
Pharmaceutical salts of biologically active hydrazone compound salinazid: Crystallographic, solubility, and thermodynamic aspects
Surov, Artem O.,Voronin, Alexander P.,Simagina, Anna A.,Churakov, Andrei V.,Perlovich, German L.
, p. 2605 - 2617 (2016)
The crystal structures of salts of the active pharmaceutical ingredient (API) called salinazid with dicarboxylic acids and acesulfame were determined by single-crystal X-ray diffraction method. The crystals contain hydrogen bond motifs of different structure and complexity, the energies of which were estimated by using the quantum theory of atoms in molecules and crystals (QTAIMC) methodology. It was found that the driving force for facile the oxalate and malate salts formation is the bifurcated N+-H···O- and N+-H···O hydrogen bond synthon, while salinazid malonate is mainly stabilized via a "classic" pyridinium-carboxylate heterosynthon. The oxalate and acesulfame salts of salinazid were found to be stable during aqueous dissolution experiments, providing a substantial solubility improvement compared to pure API (33 and 18 times, respectively). However, the malonate and malate salts dissolved incongruently and rapidly underwent a solution-mediated transformation to form pure salinazid. Based on the solubility data of the stable salts and of the pure components, the Gibbs free energy of the salts formation were calculated to be -21.2 kJ·mol-1 for salinazid oxalate and -22.6 kJ·mol-1 for salinazid acesulfame.
Polymorphism in acesulfame sweetener: Structure-property and stability relationships of bending and brittle crystals
Velaga, Sitaram P.,Vangala, Venu R.,Basavoju, Srinivas,Bostr?m, Dan
, p. 3562 - 3564 (2010)
Acesulfame is found to exist in two crystalline forms of which Form I (needles) shows bending upon mechanical stress. Crystal structures explain their mechanical response. This is the first case of aliphatic organic compounds featuring a bending phenomenon. Form I is physically more stable than Form II in ambient conditions.
Synthesis and characterization of ammonium acesulfamate
Echeverria, Gustavo A.,Piro, Oscar E.,Parajon-Costa, Beatriz S.,Baran, Enrique J.
, p. 737 - 741 (2014)
Ammonium acesulfamate, (NH4)C4H4NO 4S, was prepared by the reaction of acesulfamic acid and ammonium carbonate in aqueous solution, and characterized by elemental analysis and 1H and 13C NM
Adapting decarbonylation chemistry for the development of prodrugs capable ofin vivodelivery of carbon monoxide utilizing sweeteners as carrier molecules
Brewer, Maya,Cachuela, Alyssa,De La Cruz, Ladie Kimberly,Gallo, David,Ji, Xingyue,Lu, Wen,Menshikh, Anna,Otterbein, Leo,Tan, Chalet,Wang, Binghe,Wang, Minjia,Wang, Siming,Yang, Haichun,Yang, Xiaoxiao,de Caestecker, Mark
, p. 10649 - 10654 (2021/08/20)
Carbon monoxide as an endogenous signaling molecule exhibits pharmacological efficacy in various animal models of organ injury. To address the difficulty in using CO gas as a therapeutic agent for widespread applications, we are interested in developing CO prodrugs through bioreversible caging of CO in an organic compound. Specifically, we have explored the decarboxylation-decarbonylation chemistry of 1,2-dicarbonyl compounds. Examination and optimization of factors favorable for maximal CO release under physiological conditions led to organic CO prodrugs using non-calorific sweeteners as leaving groups attached to the 1,2-dicarbonyl core. Attaching a leaving group with appropriate properties promotes the desired hydrolysis-decarboxylation-decarbonylation sequence of reactions that leads to CO generation. One such CO prodrug was selected to recapitulate the anti-inflammatory effects of CO against LPS-induced TNF-α production in cell culture studies. Oral administration in mice elevated COHb levels to the safe and efficacious levels established in various preclinical and clinical studies. Furthermore, its pharmacological efficacy was demonstrated in mouse models of acute kidney injury. These studies demonstrate the potential of these prodrugs with benign carriers as orally active CO-based therapeutics. This represents the very first example of orally active organic CO prodrugs with a benign carrier that is an FDA-approved sweetener with demonstrated safety profilesin vivo.
Preparation method of acesulfame potassium
-
Paragraph 0024; 0034; 0037-0039; 0042-0044; 0047; 0048; 0050, (2021/06/02)
The invention relates to a preparation method of acesulfame potassium. The preparation method comprises the following steps: (1) preparation of acetoacetamido-N-sulfonyl methyl ester: dissolving methyl sulfamate in a chlorinated hydrocarbon solvent, and reacting with diketene under the catalysis of strongly alkaline macroporous resin to generate an intermediate acetoacetamido-N-sulfonyl methyl ester; and (2) preparation of acesulfame potassium: carrying out cyclization reaction on acetoacetamido-N-sulfonyl methyl ester under the action of a copper pyridine complex catalyst, removing byproduct methanol through reactive distillation, and then performing KOH treatment to obtain acesulfame potassium. Compared with the existing production process, the copper pyridine complex is used for replacing a strong acid catalyst in the cyclization process, so that the polymerization side reaction of the intermediate is obviously reduced, and the product yield is increased. Meanwhile, triethylamine and SO3 are prevented from being used, and generation of waste acid and waste water is greatly reduced.
CARBON MONOXIDE PRODRUGS FOR THE TREATMENT OF MEDICAL DISORDERS
-
Page/Page column 128-131, (2020/05/21)
The present invention provides new compounds and compositions thereof that release carbon monoxide for the treatment of medical disorders that are responsive to carbon monoxide, for example, inflammatory, pain, and dermatological disorders.
PROCESS FOR THE PREPARATION OF AN ACESULFAME IN A SPRAY REACTOR HAVING A SPECIFIC VELOCITY OF FLOW
-
Page/Page column 25, (2019/07/19)
In general, the invention relates to a process for the preparation of acesulfame or a derivative thereof. More specifically, the invention relates to a process, to a product obtainable by the process and the use of a specified velocity of flow for improving yield in the preparation of acesulfame or a derivative thereof. The invention relates to a process for the preparation of a product, the product being 6-methyl-3,4-dihydro1,2,3-oxathiazin-4-one 2,2-dioxide or a derivative thereof, the process comprising the following steps: a. Contacting SO3 and acetoacetamide-N-sulfonic acid or a derivative thereof in a reactor with a reactor pressure to obtain the product; b. The product exiting the reactor to a region outside the reactor through an aperture at a velocity of flow higher than 0.9 m/s, the region outside the reactor having an external pressure which is lower than the reactor pressure.